Terms: = Lung cancer AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED
248 results:
1. NDRG2 acts as a negative regulator of the progression of small-cell lung cancer through the modulation of the PTEN-AKT-mTOR signalling cascade.
Ma Z; Ma Y; Feng J; Xu Z; Cheng C; Qin J; Li S; Jiang J; Kong R
Toxicol Appl Pharmacol; 2024 Apr; 485():116915. PubMed ID: 38537875
[TBL] [Abstract] [Full Text] [Related]
2. C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.
Lang C; Megyesfalvi Z; Lantos A; Oberndorfer F; Hoda MA; Solta A; Ferencz B; Fillinger J; Solyom-Tisza A; Querner AS; Egger F; Boettiger K; Klikovits T; Timelthaler G; Renyi-Vamos F; Aigner C; Hoetzenecker K; Laszlo V; Schelch K; Dome B
World J Surg Oncol; 2024 Feb; 22(1):57. PubMed ID: 38369463
[TBL] [Abstract] [Full Text] [Related]
3. Adult Pulmonary Blastoma: A Case Report with Spectrum of Rare Manifestations.
Parkhi M; Ahuja N; Kumar D; Basher RK; Singh N; Singh H; Bal A
Turk Patoloji Derg; 2024; 40(1):63-68. PubMed ID: 38235566
[TBL] [Abstract] [Full Text] [Related]
4. Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of mycn-amplified cancers.
Stokes ME; Vasciaveo A; Small JC; Zask A; Reznik E; Smith N; Wang Q; Daniels J; Forouhar F; Rajbhandari P; Califano A; Stockwell BR
Cell Chem Biol; 2024 Apr; 31(4):805-819.e9. PubMed ID: 38061356
[TBL] [Abstract] [Full Text] [Related]
5. Cytomorphologic and immunocytochemical characterization of pediatric pleuropulmonary blastoma with a comprehensive review of the literature.
Gupta P; Chugh S; Gupta N; Gupta K; Sodhi KS; Kakkar N; Srinivasan R; Rohilla M; Kundu R; Trehan A; Bansal D; Peters NJ
Diagn Cytopathol; 2024 Feb; 52(2):103-115. PubMed ID: 37964698
[TBL] [Abstract] [Full Text] [Related]
6. The GR-SGK1-NDRG1 Pathway as a Predictor of Recurrence and Prognosis in lung Adenocarcinoma After Radical Surgery.
Sasaki T; Nakamura Y; Hata S; Shimada H
Anticancer Res; 2023 Jul; 43(7):2965-2974. PubMed ID: 37351994
[TBL] [Abstract] [Full Text] [Related]
7. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract] [Full Text] [Related]
8. MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.
Alburquerque-Bejar JJ; Navajas-Chocarro P; Saigi M; Ferrero-Andres A; Morillas JM; Vilarrubi A; Gomez A; Mate JL; Munoz-Marmol AM; Romero OA; Blecua P; Davalos V; Esteller M; Pros E; Llabata P; Torres-Diz M; Esteve-Codina A; Sanchez-Cespedes M
Cell Rep Med; 2023 Apr; 4(4):101006. PubMed ID: 37044092
[TBL] [Abstract] [Full Text] [Related]
9. The predictive value of YAP-1 and POU2F3 for the efficacy of immuno-chemotherapy in extensive-stage SCLC patients.
Chen YQ; Gao LL; Kong LC; Guan XH; Yang H; Li YF; Lv ZY; Zhang XC; Liang HY; Chen HJ; Wu YL; Huang J; Yang JJ
Cancer Treat Res Commun; 2023; 35():100684. PubMed ID: 36716535
[TBL] [Abstract] [Full Text] [Related]
10. Clinical significance of MYC family protein expression in surgically resected high-grade neuroendocrine carcinoma of the lung.
Oshima Y; Haruki T; Matsui S; Makishima K; Sakabe T; Umekita Y; Nakamura H
Thorac Cancer; 2023 Mar; 14(8):758-765. PubMed ID: 36694106
[TBL] [Abstract] [Full Text] [Related]
11. Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.
Shatat MA; Gauthier B; Yoon S; Yuan E; Yang P; Narla G; Dowlati A; Lee RT
Cancer Med; 2023 Apr; 12(7):8378-8387. PubMed ID: 36562288
[TBL] [Abstract] [Full Text] [Related]
12. An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies.
Orlando E; Medo M; Bensimon A; Quintin A; Riedo R; Roth SM; Riether C; Marti TM; Aebersold DM; Medová M; Aebersold R; Zimmer Y
Cell Mol Life Sci; 2022 Dec; 80(1):6. PubMed ID: 36494469
[TBL] [Abstract] [Full Text] [Related]
13. YAP 5-methylcytosine modification increases its mRNA stability and promotes the transcription of exosome secretion-related genes in lung adenocarcinoma.
Yu W; Zhang C; Wang Y; Tian X; Miao Y; Meng F; Ma L; Zhang X; Xia J
Cancer Gene Ther; 2023 Jan; 30(1):149-162. PubMed ID: 36123390
[TBL] [Abstract] [Full Text] [Related]
14. mycn mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis.
Alborzinia H; Flórez AF; Kreth S; Brückner LM; Yildiz U; Gartlgruber M; Odoni DI; Poschet G; Garbowicz K; Shao C; Klein C; Meier J; Zeisberger P; Nadler-Holly M; Ziehm M; Paul F; Burhenne J; Bell E; Shaikhkarami M; Würth R; Stainczyk SA; Wecht EM; Kreth J; Büttner M; Ishaque N; Schlesner M; Nicke B; Stresemann C; Llamazares-Prada M; Reiling JH; Fischer M; Amit I; Selbach M; Herrmann C; Wölfl S; Henrich KO; Höfer T; Trumpp A; Westermann F
Nat Cancer; 2022 Apr; 3(4):471-485. PubMed ID: 35484422
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of GWAS-nominated loci for lung cancer and COPD revealed a new asthma locus.
Madore AM; Bossé Y; Margaritte-Jeannin P; Vucic E; Lam WL; Bouzigon E; Bourbeau J; Laprise C
BMC Pulm Med; 2022 Apr; 22(1):155. PubMed ID: 35461280
[TBL] [Abstract] [Full Text] [Related]
16. Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors
Khazan N; Kim KK; Hansen JN; Singh NA; Moore T; Snyder CWA; Pandita R; Strawderman M; Fujihara M; Takamura Y; Jian Y; Battaglia N; Yano N; Teramoto Y; Arnold LA; Hopson R; Kishor K; Nayak S; Ojha D; Sharon A; Ashton JM; Wang J; Milano MT; Miyamoto H; Linehan DC; Gerber SA; Kawar N; Singh AP; Tabdanov ED; Dokholyan NV; Kakuta H; Jurutka PW; Schor NF; Rowswell-Turner RB; Singh RK; Moore RG
J Med Chem; 2022 Apr; 65(8):6039-6055. PubMed ID: 35404047
[TBL] [Abstract] [Full Text] [Related]
17. Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients.
Hua G; Zhang X; Zhang M; Wang Q; Chen X; Yu R; Bao H; Liu J; Wu X; Shao Y; Liang B; Lu K
ESMO Open; 2022 Feb; 7(1):100337. PubMed ID: 35123209
[TBL] [Abstract] [Full Text] [Related]
18. EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation.
Wang L; Chen C; Song Z; Wang H; Ye M; Wang D; Kang W; Liu H; Qing G
Nat Commun; 2022 Jan; 13(1):12. PubMed ID: 35013218
[TBL] [Abstract] [Full Text] [Related]
19. A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.
Raman S; Buongervino SN; Lane MV; Zhelev DV; Zhu Z; Cui H; Martinez B; Martinez D; Wang Y; Upton K; Patel K; Rathi KS; Navia CT; Harmon DB; Li Y; Pawel B; Dimitrov DS; Maris JM; Julien JP; Bosse KR
Cell Rep Med; 2021 Jul; 2(7):100344. PubMed ID: 34337560
[TBL] [Abstract] [Full Text] [Related]
20. Morphologic, Immunohistochemical, and Genetic Differences Between High-grade and Low-grade Fetal Adenocarcinomas of the lung.
Li Y; Xi SY; Yong JJ; Wu XY; Yang XH; Wang F
Am J Surg Pathol; 2021 Nov; 45(11):1464-1475. PubMed ID: 34138800
[TBL] [Abstract] [Full Text] [Related]
[Next]
